Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki

Oculis announced completion of randomization in the PREDICT-1 registrational trial for Licaminlimab, a precision medicine treatment for TNFR1-mediated dry eye disease. The trial enrolled 176 patients, with two-thirds carrying the specific TNFR1 genetic variant associated with improved clinical response. Topline results are expected around year-end 2026. If approved, Licaminlimab could become the first precision medicine treatment for an estimated 1.5 million Americans with moderate to severe TNFR1-mediated dry eye disease.